Toggle light / dark theme

00:00 Intro.
01:12 Elon Musk on psychedelics/ MDMA
01:58 Tim Urban on brain-machine interfaces.
02:46 Domino’s mind ordering app.
04:48 Elon tweet: digital vs biological.
05:47 Head Neurosurgeon, Dr. Matthew MacDougall.
08:02 Shivon Zilis & Elon Musk twins!!
09:05 Neuralink founder, Paul Merolla departs.
11:17 https://neuralink.com/careers/
11:35 DeepMind Documentary: https://youtu.be/kFlLzFuslfQ

Patreon: https://www.patreon.com/neurapod/

Neura Pod is a series covering topics related to Neuralink, Inc. Topics such as brain-machine interfaces, brain injuries, and artificial intelligence will be explored. Host Ryan Tanaka synthesizes informationopinions, and conducts interviews to easily learn about Neuralink and its future.

Please consider supporting by joining the channel above, or sharing my other company website with retirees: https://www.reterns.com/. Opinions are my own. Neura Pod receives no compensation from Neuralink and has no affiliation to the company.

Visit https://brilliant.org/isaacarthur/ to get started learning STEM for free, and the first 200 people will get 20% off their annual premium subscription.
We often wonder where all the aliens are out in the galaxy, but could it be that the technologies needed to get to space and travel the stars lead to inevitable catastrophe?

Visit our Website: http://www.isaacarthur.net.
Support us on Patreon: https://www.patreon.com/IsaacArthur.
Support us on Subscribestar: https://www.subscribestar.com/isaac-arthur.
Facebook Group: https://www.facebook.com/groups/1583992725237264/
Reddit: https://www.reddit.com/r/IsaacArthur/
Twitter: https://twitter.com/Isaac_A_Arthur on Twitter and RT our future content.
SFIA Discord Server: https://discord.gg/53GAShE

Listen or Download the audio of this episode from Soundcloud: Episode’s Audio-only version: https://soundcloud.com/isaac-arthur-148927746/the-fermi-para…-timebombs.
Episode’s Narration-only version: https://soundcloud.com/isaac-arthur-148927746/the-fermi-para…ation-only.

Credits:

A University of Minnesota Twin Cities-led team has found that electrical stimulation of the body combined with sound activates the brain’s somatosensory or “tactile” cortex, increasing the potential for using the technique to treat chronic pain and other sensory disorders. The researchers tested the non-invasive technique on animals and are planning clinical trials on humans in the near future.

The paper is published in the Journal of Neural Engineering, a highly regarded, peer-reviewed scientific journal for the interdisciplinary field of neural engineering.

During the experiments, the researchers played broadband sound while electrically stimulating different parts of the body in guinea pigs. They found that the combination of the two activated neurons in the brain’s somatosensory cortex, which is responsible for touch and pain sensations throughout the body.

“The Commission determined that these applications failed to demonstrate that the providers could deliver the promised service,” the FCC said in a statement.

FCC Chairwoman Jessica Rosenworcel added: “We cannot afford to subsidize ventures that are not delivering the promised speeds or are not likely to meet program requirements.”

In December 2020, the FCC tentatively awarded $886 million to SpaceX to help its Starlink service supply high-speed broadband to 642,925 locations in 35 states. However, it came with a requirement (Opens in a new window) that SpaceX provide a long-form application about how Starlink would meet its obligations before the federal funding could be fully secured.

The signaling protein, known as mTOR, is excessively active in many cancer cells and plays a key role in various diseases, such as diabetes, inflammation, and aging. Meanwhile, autophagy is well-known for its elaborately mediated regulation of activity by the mTOR protein in cells. Inhibiting this activity of the mTOR protein can increase autophagy and subsequently induce cancer cell death.

Professor Kim Se-yun’s research team conducted a study on developing an mTOR-inhibitory anticancer drug with a drug regeneration strategy based on effective binding technology that models physical interactions between compounds and target proteins using the three-dimensional protein structure.

Drug regeneration finds new indications for FDA-approved drugs or clinical drug groups previously proven safe. According to the researchers, this strategy can innovatively shorten the enormous time and investment in new drug development that traditionally takes more than 10 years.